Radioisotope Treatment for Pancreatic Cancer Using Listeria Bacteria

Pancreatic cancer is a type of cancer that can lead to loss of life because of the difficulty of early diagnosis and the risk of rapid spread. In a new study conducted at Yeshiva University, Albert Einstein College of Medicine, a significant advance was achieved in the treatment of pancreatic cancer by infecting the tumor with a bacterium called Listeria and delivering a radioisotope. The study found a substantial reduction in the number of tumors that had spread to other parts of the body. Moreover, this method, which was observed to be effective against highly aggressive pancreatic cancers, does not damage healthy cells. This method may have significant potential for reducing cancer metastases. The researchers believe that the treatment could be improved with a more detailed treatment plan. These promising studies are intended to remain successful in the subsequent stages as well.
Radioisotope Treatment for Pancreatic Cancer Using Listeria Bacteria
The researchers administered radioisotope treatment by infecting the tumor with a bacterium called Listeria. This method was shown to be effective against highly aggressive pancreatic cancers without damaging healthy cells.
Animal studies
Although human trials have not yet been conducted, the research is progressing through promising animal studies. In a study conducted on mice with metastatic pancreatic cancer, injecting radioactive Listeria was found to reduce metastasis by %90.
Hope for the future
The researchers state that treatment plans could be more detailed and that the treatment could be improved by using higher doses of radiation or adding anticancer agents to the bacteria. It is hoped that such studies will also be successful in the future.
Conclusion
The treatment of a disease such as pancreatic cancer, which can lead to loss of life, has always been a major challenge. However, because radioisotope treatment with Listeria bacteria has shown promising results, it has the potential to be used as a treatment method in the future.
Sources
2. Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33(12):1325-1333. doi:10.1200/JCO.2014.57.4244
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.